Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.
Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
It is a two dose vaccine to be administered intramuscularly at 28 days apart
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Subscribe To Our Newsletter & Stay Updated
